Cargando…

Toll-like receptor 9 agonist enhances anti-tumor immunity and inhibits tumor-associated immunosuppressive cells numbers in a mouse cervical cancer model following recombinant lipoprotein therapy

BACKGROUND: Although cytotoxic T lymphocytes (CTLs) play a major role in eradicating cancer cells during immunotherapy, the cancer-associated immunosuppressive microenvironment often limits the success of such therapies. Therefore, the simultaneous induction of cancer-specific CTLs and reversal of t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chang, Li-Sheng, Leng, Chih-Hsiang, Yeh, Yi-Chen, Wu, Chiao-Chieh, Chen, Hsin-Wei, Huang, Hai-Mei, Liu, Shih-Jen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2014
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4000133/ https://www.ncbi.nlm.nih.gov/pubmed/24642245 http://dx.doi.org/10.1186/1476-4598-13-60

Ejemplares similares

A Toll-like receptor 2 agonist-fused antigen enhanced antitumor immunity by increasing antigen presentation and the CD8 memory T cells population
por: Wu, Chiao-Chieh, et al.
Publicado: (2016)

Liposomal TLR9 Agonist Combined with TLR2 Agonist-Fused Antigen Can Modulate Tumor Microenvironment through Dendritic Cells
por: Shen, Kuan-Yin, et al.
Publicado: (2020)

Recombinant lipoprotein-based vaccine candidates against C. difficile infections
por: Huang, Jui-Hsin, et al.
Publicado: (2015)

Efficient Uptake of Recombinant Lipidated Survivin by Antigen-Presenting Cells Initiates Antigen Cross-Presentation and Antitumor Immunity
por: Chiang, Chen-Yi, et al.
Publicado: (2018)

Depletion of tumor-associated macrophages enhances the anti-tumor immunity induced by a Toll-like receptor agonist-conjugated peptide
por: Shen, Kuan-Yin, et al.
Publicado: (2014)

Delivery of Antigen to CD8(+) Dendritic Cells by Fusing Antigen With Formyl Peptide Receptor-Like 1 Inhibitor Protein Induces Antitumor Immunity
por: Chiang, Chen-Yi, et al.
Publicado: (2019)

Anti-tumor Activity of Toll-Like Receptor 7 Agonists
por: Chi, Huju, et al.
Publicado: (2017)

The Role of Toll-like Receptor Agonists and Their Nanomedicines for Tumor Immunotherapy
por: Huang, Lingling, et al.
Publicado: (2022)

A Purified Recombinant Lipopeptide as Adjuvant for Cancer Immunotherapy
por: Song, Ying-Chyi, et al.
Publicado: (2014)

A Novel Recombinant Fcγ Receptor-Targeted Survivin Combines with Chemotherapy for Efficient Cancer Treatment
por: Wu, Chiao-Chieh, et al.
Publicado: (2021)

Immunosuppressive Roles of Galectin-1 in the Tumor Microenvironment
por: Huang, Yanyu, et al.
Publicado: (2021)

Toll-like Receptor-4 Activation Boosts the Immunosuppressive Properties of Tumor Cells-derived Exosomes
por: Domenis, Rossana, et al.
Publicado: (2019)

Recombinant Lipidated HPV E7 Induces a Th-1-Biased Immune Response and Protective Immunity against Cervical Cancer in a Mouse Model
por: Huang, Chiung-Yi, et al.
Publicado: (2012)

Antibody conjugates for targeted delivery of Toll-like receptor 9 agonist to the tumor tissue
por: Corogeanu, Diana, et al.
Publicado: (2023)

Sustained Intratumoral Administration of Agonist CD40 Antibody Overcomes Immunosuppressive Tumor Microenvironment in Pancreatic Cancer
por: Liu, Hsuan‐Chen, et al.
Publicado: (2023)

Immunogenicity of a novel tetravalent vaccine formulation with four recombinant lipidated dengue envelope protein domain IIIs in mice
por: Chiang, Chen-Yi, et al.
Publicado: (2016)

A toll-like receptor agonist mimicking microbial signal to generate tumor-suppressive macrophages
por: Feng, Yanxian, et al.
Publicado: (2019)

Carboxyl-terminal fusion of E7 into Flagellin shifts TLR5 activation to NLRC4/NAIP5 activation and induces TLR5-independent anti-tumor immunity
por: Lin, Kuo-Hsing, et al.
Publicado: (2016)

CpG-oligodeoxynucleotides developed for grouper toll-like receptor (TLR) 21s effectively activate mouse and human TLR9s mediated immune responses
por: Yeh, Da-Wei, et al.
Publicado: (2017)

Recombinant lipidated Zika virus envelope protein domain III elicits durable neutralizing antibody responses against Zika virus in mice
por: Chen, Mei-Yu, et al.
Publicado: (2020)

Expression of Toll-Like Receptors on Breast Tumors: Taking a Toll on Tumor Microenvironment
por: Bhattacharya, Debika, et al.
Publicado: (2012)

A RAD51–ADP double filament structure unveils the mechanism of filament dynamics in homologous recombination
por: Luo, Shih-Chi, et al.
Publicado: (2023)

Solitary fibrous tumor of the scrotum: a case report and review of the literature
por: Chang, Tsung-Hsin, et al.
Publicado: (2019)

Mycobacterium tuberculosis lipoprotein LprG (Rv1411c) binds triacylated glycolipid agonists of Toll-like receptor 2
por: Drage, Michael G., et al.
Publicado: (2010)

Recent Advances in the Development of Toll-like Receptor Agonist-Based Vaccine Adjuvants for Infectious Diseases
por: Yang, Jing-Xing, et al.
Publicado: (2022)

Inhibition and promotion of tumor growth with adeno-associated virus carcinoembryonic antigen vaccine and Toll like receptor agonists
por: Triozzi, Pierre L., et al.
Publicado: (2011)

A Flagellin-Derived Toll-Like Receptor 5 Agonist Stimulates Cytotoxic Lymphocyte-Mediated Tumor Immunity
por: Leigh, Nicholas D., et al.
Publicado: (2014)

Exosome-Mediated Immunosuppression in Tumor Microenvironments
por: Xie, Qi-Hui, et al.
Publicado: (2022)

Serum lipoproteins attenuate macrophage activation and Toll-Like Receptor stimulation by bacterial lipoproteins
por: Bas, Sylvette, et al.
Publicado: (2010)

Activation of GM-CSF and TLR2 signaling synergistically enhances antigen-specific antitumor immunity and modulates the tumor microenvironment
por: Yan, Wan-Lun, et al.
Publicado: (2021)

Toll-Like Receptor 9 Agonists in Cancer
por: Karapetyan, Lilit, et al.
Publicado: (2020)

A TLR9 agonist enhances the anti-tumor immunity of peptide and lipopeptide vaccines via different mechanisms
por: Song, Ying-Chyi, et al.
Publicado: (2015)

Sustained Intratumoral Administration of Agonist CD40 Antibody Overcomes Immunosuppressive Tumor Microenvironment in Pancreatic Cancer (Adv. Sci. 9/2023)
por: Liu, Hsuan‐Chen, et al.
Publicado: (2023)

Dendritic cell vaccination with a toll-like receptor agonist derived from mycobacteria enhances anti-tumor immunity
por: Vo, Manh-Cuong, et al.
Publicado: (2015)

Combinations of Toll-like receptor 8 agonist TL8-506 activate human tumor-derived dendritic cells
por: He, Mi, et al.
Publicado: (2022)

Toll-Like Receptor 9 Agonists for Cancer Therapy
por: Melisi, Davide, et al.
Publicado: (2014)

Toll-Like Receptor Agonists as Adjuvants for Allergen Immunotherapy
por: Kirtland, Max E., et al.
Publicado: (2020)

Sedative and Immunosuppressive Effects of Dexmedetomidine in Transplantation
por: Lee, Chen-Fang, et al.
Publicado: (2021)

Immunosuppressive Phenotype of Esophagus Tumors Stroma
por: Kovaleva, Olga V., et al.
Publicado: (2020)

Tumor-Derived Exosomes in Immunosuppression and Immunotherapy
por: Olejarz, Wioletta, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_shbgvonkdmdbta8d4mnttrig38